All In Biotech

Drug Trial Radar · NCT01545076

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study

Last checked: Nov 19, 2026Latest source record: Jul 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

208

Actual

Start

Mar 2012

Primary completion

Sep 2016

Study completion Sep 2016

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
Collaborators
ICON Clinical Research
First posted
Mar 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of patients with CIDP. Patients who received at lease 1 dose of intravenous immunoglobulin (IVIG) within 8 weeks before screening will be assessed during 4 separate study periods. Patients first undergo a Screening Period, followed by an IgG Dependency Test Period of up to 12 weeks to test for ongoing need of IgG. Those patients experiencing CIDP relapse during this test period will be administered a standardized IVIG regimen during an IVIG Re-stabilization Period. Patients with improved and maintained adjusted inflammatory neuropathy cause and treatment scale (INCAT) in the IVIG Re-stabilization Period will continue to the SC Treatment Period of the study. Patients entering the 24 week SC Treatment Period will be randomized to receive weekly infusions of 1 of 2 IgPro20 doses (0.2 or 0.4 g/kg body weight) or placebo. The overall study duration is up to 52 weeks. Clinical outcomes will be assessed by the Inflammatory Neuropathy Cause and Treatment (INCAT) score, maximum grip strength, the Medical Research Council (MRC) sum score, the Rasch-built Overall Disability Scale (R-ODS), and electrophysiological evaluations.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Polyradiculoneuropathy

Interventions

  • IgPro20 (low dose)Biological

    20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization: 0.2 g/kg body weight (low dose arm)

  • PlaceboBiological

    2% human albumin administered by weekly SC infusions during the SC treatment period of the study.

  • IgPro10Biological

    10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.

  • IgPro20 (high dose)Biological

    20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization: 0.4 g/kg body weight (high dose arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment PeriodTime frame: Up to 25 weeks

Locations

91 sites in 16 countries. Site status is shown where the registry gives one.

  • Site reference 8400181

    Birmingham, Alabama

  • Site reference 8400173

    Phoenix, Arizona

  • Site reference 8400172

    Phoenix, Arizona

  • Site reference 8400167

    Los Angeles, California

  • Site reference 8400077

    Centennial, Colorado

  • Site Reference 8400352

    Washington D.C., District of Columbia

  • Site reference 8400214

    Miami, Florida

  • Site reference 8400162

    Chicago, Illinois

  • Site Reference 8400247

    Chicago, Illinois

  • Site Reference 8400215

    Indianapolis, Indiana

  • Site reference 8400166

    Kansas City, Kansas

  • Site Reference 8400347

    New Brunswick, New Jersey

  • Site reference 8400169

    New York, New York

  • Site reference 8400179

    New York, New York

  • Site reference 8400182

    Charlotte, North Carolina

  • Site Reference 8400346

    Durham, North Carolina

  • Site reference 8400178

    Columbus, Ohio

  • Site reference 8400217

    Oklahoma City, Oklahoma

  • Site Reference 8400177

    Nashville, Tennessee

  • Site reference 8400164

    Houston, Texas

  • Site Reference 8400268

    Charlottesville, Virginia

  • Site Reference 8400340

    Seattle, Washington

  • Site reference 0360008

    Southport, Australia

  • Site Reference 0360017

    Herston, Queensland, Australia

  • Site reference 0360011

    Fitzroy, Victoria, Australia

  • Site reference 0560003

    Leuven, Belgium

  • Site reference 1240006

    Edmonton, Canada

  • Site reference 1240007

    Québec, Canada

  • Site reference 1240009

    Toronto, Canada

  • Site Reference 1240048

    Vancouver, British Columbia, Canada

  • Site Reference 1240051

    Montreal, Quebec, Canada

  • Site reference 2030002

    Hradec Králové, Czechia

  • Site reference 2030009

    Hradec Králové, Czechia

  • Site reference 2030003

    Prague, Czechia

  • Site Reference 2330002

    Tallinn, Estonia

  • Site Reference 2330003

    Tallinn, Estonia

  • Site reference 2460002

    Helsinki, Finland

  • Site reference 2500024

    Clermont-Ferrand, France

  • Site reference 2500013

    Marseille, France

  • Site reference 2500022

    Nice, France

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.